Upgrade to Pro — share decks privately, control downloads, hide ads and more …

Untitled_document_-_2026-10-27T193518.376.pdf

sanakhan
October 27, 2026
8

 Untitled_document_-_2026-10-27T193518.376.pdf

sanakhan

October 27, 2026

Transcript

2 slides
  1. Building an AI-Ready Pharma Commercial Operating Model in 2026 Pharmaceutical

    companies are entering 2026 with growing pressure to improve commercial effectiveness while responding faster to changing customer expectations, market access conditions, and competitive dynamics. Artificial intelligence can support this shift, but successful adoption requires more than adding new technologies. An AI-ready commercial operating model connects data, people, processes, governance, and technology around measurable business outcomes. Current industry research similarly emphasizes that fragmented data, workflows, and governance can prevent AI investments from delivering scalable value. Establish a Clear Commercial Vision The first step is defining where AI can create meaningful commercial value. Organizations should assess activities such as customer segmentation, sales-force effectiveness, forecasting, competitive intelligence, pricing, marketing analytics, and customer engagement. A clear vision helps prioritize high-impact use cases instead of deploying disconnected AI pilots. A modern model should also align commercial, medical, analytics, technology, compliance, and other specialist teams around common objectives. This connected approach can help organizations move from isolated initiatives toward coordinated decision-making. Build a Trusted Data Foundation AI performance depends heavily on the quality, accessibility, and context of the underlying data. Pharma organizations should establish governed data foundations that connect relevant customer, market, sales, prescription, claims, and engagement information where legally and operationally appropriate. Data should be standardized, traceable, secure, and accessible to authorized users. Strong data governance also helps reduce inconsistencies between departments and gives AI systems a more reliable foundation for forecasting and decision support. Redesign Commercial Workflows for AI Simply adding AI to existing processes can limit its potential. Instead, organizations should identify repetitive or decision-intensive workflows that can be redesigned around intelligent automation and predictive insights.
  2. For example, AI can help identify emerging customer patterns, improve

    territory planning, prioritize engagement opportunities, and generate insights for commercial teams. The objective is not to replace expert judgment but to help teams make faster, more informed decisions. The broader Pharma Commercial Operations function should therefore evolve from process execution toward continuous, insight-led orchestration. Embed Responsible AI Governance Pharmaceutical commercialization requires strong controls because decisions can affect regulated communications, customer interactions, privacy, and business outcomes. An AI-ready model should define accountability for model development, validation, monitoring, data usage, security, and human review. Human oversight remains particularly important for high-impact decisions. Organizations should establish clear escalation mechanisms, documentation requirements, performance monitoring, and auditability so AI-supported decisions can be evaluated and defended. Develop AI-Ready Talent and Ways of Working Technology alone cannot create transformation. Commercial teams need sufficient AI literacy to understand how models work, interpret outputs, recognize limitations, and apply insights appropriately. Cross-functional collaboration should become part of the operating model, bringing together commercial specialists, data scientists, technology teams, compliance professionals, and subject-matter experts. This combination of business expertise and AI capability can improve adoption while reducing implementation risks. Measure Business Impact and Scale Gradually AI initiatives should be evaluated against measurable outcomes such as forecast accuracy, campaign effectiveness, customer engagement, productivity, decision-cycle time, and commercial performance. Establishing these measures early makes it easier to identify successful use cases and scale them responsibly. In 2026, the strongest pharma organizations will increasingly treat AI readiness as an operating-model transformation rather than a technology project. By connecting trusted data, redesigned workflows, responsible governance, skilled teams, and measurable outcomes, companies can create a commercial organization that is more adaptive, intelligent, and prepared for continuous change.